Tirzepatide

Common brands: Mounjaro Kwikpen, Mounjaro, Zepbound Kwikpen, Zepbound, Metformin Hydrochloride

Top reporter: Eli Lilly And Company

GLP-1 Receptor Agonist [EPC]Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Insulin Analog [EPC]Sodium-Glucose Cotransporter 2 Inhibitor [EPC]
140,435
Total Reports
140,069
Serious Reports
775
Death Reports
30
Reported Reactions
Death Report Ratio: Low (0.55%)

Patient Demographics

Male
27,613
Female
85,258

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Tirzepatide.

# Reaction Reports % of Total
1 INCORRECT DOSE ADMINISTERED 28,115
17.4%
2 NAUSEA 14,290
8.9%
3 INJECTION SITE PAIN 13,177
8.2%
4 EXTRA DOSE ADMINISTERED 9,000
5.6%
5 DIARRHOEA 8,305
5.2%
6 OFF LABEL USE 8,291
5.1%
7 VOMITING 6,887
4.3%
8 DRUG INEFFECTIVE 5,415
3.4%
9 CONSTIPATION 5,248
3.3%
10 INJECTION SITE HAEMORRHAGE 5,035
3.1%
11 INJECTION SITE ERYTHEMA 4,771
3.0%
12 ACCIDENTAL UNDERDOSE 4,607
2.9%
13 PRODUCT DOSE OMISSION ISSUE 4,162
2.6%
14 FATIGUE 3,845
2.4%
15 INJECTION SITE BRUISING 3,266
2.0%
16 ABDOMINAL PAIN UPPER 3,085
1.9%
17 HEADACHE 2,908
1.8%
18 BLOOD GLUCOSE INCREASED 2,809
1.7%
19 DECREASED APPETITE 2,730
1.7%
20 WEIGHT INCREASED 2,660
1.6%
21 INJECTION SITE PRURITUS 2,601
1.6%
22 DIZZINESS 2,472
1.5%
23 ERUCTATION 2,462
1.5%
24 ILLNESS 2,448
1.5%
25 ABDOMINAL PAIN 2,211
1.4%
26 DYSPEPSIA 2,208
1.4%
27 WEIGHT DECREASED 2,122
1.3%
28 ALOPECIA 2,099
1.3%
29 ACCIDENTAL OVERDOSE 2,023
1.3%
30 INJECTION SITE REACTION 2,009
1.2%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.